Matthew Dzajkowski, a veteran financial officer with two North Carolina firms, is the new chief financial officer at Aldagen.
Aldagen, which closed on $14 million in Series C venture financing in December, is focused on development of regenerative technologies based on stem cell research.
Dzajkowski helped lead Pozen Pharmaceuticals through its initial public offering. He also was part of the management team that led the financial turnaround of once bankrupt AAIPharma. Dzajowski had worked at AAIPharma, which is now privately held, since 2004.
Overall, Dzajowski has more than 25 years of financial management experience.
"Matt’s experience in managing the financing efforts of private and public biotech companies will be a tremendous asset to us as we pursue future financing and strategic options," said Tom Amick, chairman and Chief Executive Officer of Aldagen. "His banking experience and strong administrative and operational skills will benefit Aldagen as we continue to build an organization capable of commercializing our products."